Health
Lilly to present data from two positive Phase 3 studies of Jaypirca (pirtobrutinib) in chronic lymphocytic leukemia at the 2025 American Society of Hematology (ASH) Annual Meeting
Eli Lilly and Company (NYSE: LLY) today announced that data from studies of Jaypirca (pirtobrutinib), the first and only approved non-covalent (reversible) Bruton tyrosine kinase (BTK) inhibitor, will be presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place Dec. 6-9 in Orlando, Florida.
About this update from Eli Lilly And Company
[{"type":"text","content":"Results from the BRUIN CLL-314 study comparing Jaypirca (pirtobrutinib) to Imbruvica (ibrutinib) – the first-ever head-to-head Phase 3 study versus a covalent BTK inhibitor to include treatment-naïve CLL/SLL patients – will be presented as an oral presentation","length":260,"tagName":"p","attribs":{}},{"type":"text","content":"Results from the Phase 3 BRUIN CLL-313 study of pirtobrutinib in patients with treatment-naïve CLL/SLL will be featured as a late-breaking oral presentation","length":156,"tagName":"p","attribs":{}},{"type":"text","content":"Both BRUIN CLL-314 and BRUIN CLL-313 were selected to be part of the official ASH press program","length":95,"tagName":"p","attribs":{}},{"type":"text","content":"INDIANAPOLIS, Nov. 24, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from studies of Jaypirca (pirtobrutinib), the first and only approved non-covalent (reversible) Bruton tyrosine kinase (BTK) inhibitor, will be presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place Dec. 6-9 in Orlando, Florida.","length":380,"tagName":"p"},{"type":"text","content":"Key data presentations for Jaypirca include:","length":44,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"In an oral presentation, Lilly will share results from the BRUIN CLL-314 study, comparing pirtobrutinib to Imbruvica (ibrutinib), a covalent BTK inhibitor, in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL). Lilly previously announced that pirtobrutinib met the primary endpoint of response rate non-inferiority, favoring pirtobrutinib with a nominal P-value for superiority < 0.05. BRUIN CLL-314 is the first-ever head-to-head Phase 3 study versus a covalent BTK inhibitor to include treatment-naïve patients. These results were also selected to be highlighted in the ASH Annual Meeting press program session on Dec. 7.","length":658,"tagName":"p"}]},{"val":[{"type":"text","content":"In a late-breaking oral presentation, Lilly will share results from the Phase 3 BRUIN CLL-313 study of pirtobrutinib versus chemoimmunotherapy in patients with treatment-naïve CLL/SLL without del(17p). Lilly previously announced the study met its primary endpoint, demonstrating a highly statistically significant and clinically meaningful improvement in progres...